DK1965797T3 - Nedsættelse af svimmelhed, en bivirkning forbundet med pirfenidonterapi - Google Patents

Nedsættelse af svimmelhed, en bivirkning forbundet med pirfenidonterapi

Info

Publication number
DK1965797T3
DK1965797T3 DK06838621.8T DK06838621T DK1965797T3 DK 1965797 T3 DK1965797 T3 DK 1965797T3 DK 06838621 T DK06838621 T DK 06838621T DK 1965797 T3 DK1965797 T3 DK 1965797T3
Authority
DK
Denmark
Prior art keywords
dizziness
reduction
side effect
pirfenidone
effect associated
Prior art date
Application number
DK06838621.8T
Other languages
Danish (da)
English (en)
Inventor
Cynthia Y Robinson
Jeffery Stuart Loutit
Michelle M Freemer
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37807840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1965797(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Application granted granted Critical
Publication of DK1965797T3 publication Critical patent/DK1965797T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
DK06838621.8T 2005-12-02 2006-11-29 Nedsættelse af svimmelhed, en bivirkning forbundet med pirfenidonterapi DK1965797T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74197605P 2005-12-02 2005-12-02
PCT/US2006/045750 WO2007064738A1 (en) 2005-12-02 2006-11-29 Methods of reducing adverse events associated with pirfenidone therapy

Publications (1)

Publication Number Publication Date
DK1965797T3 true DK1965797T3 (da) 2011-05-02

Family

ID=37807840

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06838621.8T DK1965797T3 (da) 2005-12-02 2006-11-29 Nedsættelse af svimmelhed, en bivirkning forbundet med pirfenidonterapi

Country Status (13)

Country Link
US (1) US20070203202A1 (OSRAM)
EP (2) EP1965797B1 (OSRAM)
JP (3) JP5175740B2 (OSRAM)
AT (1) ATE497766T1 (OSRAM)
CA (1) CA2631646C (OSRAM)
CY (1) CY1111355T1 (OSRAM)
DE (1) DE602006020070D1 (OSRAM)
DK (1) DK1965797T3 (OSRAM)
ES (2) ES2565190T3 (OSRAM)
PL (1) PL1965797T3 (OSRAM)
PT (1) PT1965797E (OSRAM)
SI (1) SI1965797T1 (OSRAM)
WO (1) WO2007064738A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
US7767700B2 (en) 2006-12-18 2010-08-03 Intermune, Inc. Method of providing pirfenidone therapy to a patient
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
CN101842355A (zh) 2007-06-20 2010-09-22 奥斯拜客斯制药有限公司 作为纤维化抑制剂的取代的n-芳基吡啶酮
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
BRPI1006979A2 (pt) * 2009-01-26 2016-04-12 Intermune Inc métodos para tratar infartos agudos do miocárdio e distúrbios associados
US8084475B2 (en) * 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
EP4059499A1 (en) 2011-01-31 2022-09-21 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9018232B2 (en) * 2011-03-08 2015-04-28 Auspex Pharmaceuticals, Inc. Substituted N-aryl pyridinones
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
RU2605319C2 (ru) * 2011-09-14 2016-12-20 Сионоги Энд Ко., Лтд. Фармацевтическая композиция для ингаляции
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
EP2968292A4 (en) 2013-03-15 2016-11-23 Intermune Inc METHOD FOR IMPROVING MICROVASCULAR INTEGRITY
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
WO2021107060A1 (ja) * 2019-11-27 2021-06-03 塩野義製薬株式会社 ピルフェニドンの副作用を軽減するための医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
KR100777169B1 (ko) * 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
WO2004110245A2 (en) * 2003-05-16 2004-12-23 Intermune, Inc. Combination therapy for cancer treatment
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy

Also Published As

Publication number Publication date
HK1151726A1 (en) 2012-02-10
ATE497766T1 (de) 2011-02-15
CA2631646A1 (en) 2007-06-07
EP1965797B1 (en) 2011-02-09
JP2012229275A (ja) 2012-11-22
HK1123213A1 (en) 2009-06-12
PL1965797T3 (pl) 2011-07-29
JP5175740B2 (ja) 2013-04-03
JP2009518293A (ja) 2009-05-07
ES2385935T3 (es) 2012-08-03
CY1111355T1 (el) 2015-08-05
CA2631646C (en) 2016-07-26
EP2316453B1 (en) 2016-01-06
JP2015061888A (ja) 2015-04-02
DE602006020070D1 (de) 2011-03-24
EP2316453A1 (en) 2011-05-04
WO2007064738A1 (en) 2007-06-07
US20070203202A1 (en) 2007-08-30
SI1965797T1 (sl) 2011-03-31
PT1965797E (pt) 2011-05-12
EP1965797A1 (en) 2008-09-10
ES2565190T3 (es) 2016-04-01

Similar Documents

Publication Publication Date Title
CY1111355T1 (el) Μειωση της ζαλης, μια παρενεργεια που συσχετιζεται με την θεραπεια πιρφενιδονης
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
WO2004075832A3 (en) Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
CY1112478T1 (el) Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
MX2009006007A (es) Profarmacos y metodos para hacer y usar los mismos.
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
DK2043637T3 (da) Fremgangsmåder og medikamenter til administrering af ibuprofen
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
TW200716628A (en) Novel compounds
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
SE0400184D0 (sv) New therapeutical use
WO2006119389A3 (en) Quinine-containing controlled-release formulations
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
ATE540690T1 (de) Insulinkombinationen
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2008091704A3 (en) Treatment of cushing's syndrome and autism
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
WO2006133194A3 (en) Methods for treating viral infection with oral or injectible drug solution